Sustainable Production Method Could Advance Pharmaceuticals and Plastics
News Feb 13, 2018 | Original story from The University of Texas at Austin
University of Texas engineers show off their school spirit by molding the new, sustainably produced plastic material into a Longhorn silhouette in Hal Alper's lab. Credit: Cockrell School of Engineering, The University of Texas at Austin
A team of chemical engineers at The University of Texas at Austin has developed a new, cost-effective method for synthetically producing a biorenewable platform chemical called triacetic acid lactone (TAL) that can be used to produce innovative new drugs and sustainable plastics at an industrial scale, as described this week in Proceedings of the National Academy of Sciences.
Led by Hal Alper, professor in the McKetta Department of Chemical Engineering in the Cockrell School of Engineering, the team’s new method involves engineering the yeast Y. lipolytica to increase production of TAL, a polyketide, to levels that far exceed current bioproduction methods. This was accomplished by rewiring metabolism in the yeast through synthetic biology and genetic engineering. Ultimately, the research team increased production capacity tenfold, enabling polyketides to be mass-produced for incorporation into a variety of new applications in industry.
Polyketides are an important class of naturally derived molecules that can be used to make many useful products such as nutritional supplements, specialty polymers, pigments and pharmaceuticals. Currently, there are more than 20 drugs derived from polyketides on the market, including immunosuppressants, statins and antimicrobials.
Up to this point, synthetic production of polyketides has been constrained by technical challenges, limiting practical applications for consumer- and industry-based needs. In particular, most technologies have limited product yields resulting in difficult chemical synthesis and poor economics. The UT Austin team’s breakthrough could change that.
Using their new method, the researchers were able to purify TAL directly from a bioreactor to make a new plastic material that can be formed into a film and is seen to exhibit an orange hue and relative transparency.
“We hope to open up new product and industrial opportunities in the chemical and pharmaceutical spaces,” Alper said. “Our engineering efforts in TAL showcase that we can rewire metabolism to create renewable solutions to traditional chemical manufacturing.”
The UT Austin Office of Technology Commercialization has filed U.S. patent applications for the technology and is working to secure worldwide patents. The office is seeking commercial partners who have interest in improving the economics of polyketide production or creating new materials or products from polyketides.
“An important role for our institution, as one of the nation’s leading public research universities, is to move UT Austin’s research from the laboratory to useful products and services for the marketplace,” said Dan Sharp, director of the UT Austin Office of Technology Commercialization. “Research like this addresses that priority and provides society with innovative solutions that grow our economy and improve the quality of life.”
This article has been republished from materials provided by The University of Texas at Austin. Note: material may have been edited for length and content. For further information, please contact the cited source.
Artificial Leaf Acts as a Mini Medicine FactoryNews
Using sunlight for sustainable and cheap production of, for example, medicines. The 'mini-factory' in the form of a leaf that was presented in 2016 showed that it is possible. Now researchers have come with an improved version: their 'mini-factory' is now able to keep production at the same level, irrespective of the variation in sunlight due to cloudiness or time of the day.READ MORE
Non-Coding DNA Variants Increase Autism RiskNews
Whilst the contribution of gene variants to autism risk is well-established, the contribution of the 98% of the genome that does not code for gene sequences is still relatively unknown. Now, a new study has identified regulatory elements as potential genetic risk factors.READ MORE
Comments | 0 ADD COMMENT
15th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry
Sep 09 - Sep 12, 2018
CE in the Biotechnology & Pharmaceutical Industries: 20th Symposium on the Practical Applications for the Analysis of Proteins, Nucleotides & Small Molecules
Sep 09 - Sep 12, 2018